Difference between revisions of "SUIT-014 O2 pfi D042"
From Bioblast
Line 10: | Line 10: | ||
__TOC__ | __TOC__ | ||
{{Template:SUIT-014}} | {{Template:SUIT-014}} | ||
Line 42: | Line 29: | ||
::::* [[SUIT-012]]: 1PM;2D;2c;3G;4U-; shorter version with PM preceding PGM and omitting S. | ::::* [[SUIT-012]]: 1PM;2D;2c;3G;4U-; shorter version with PM preceding PGM and omitting S. | ||
== References == | |||
{{#ask:[[Category:Publications]] [[Additional label::SUIT-014 O2 pfi D042]] | |||
| ?Was published in year=Year | |||
| ?Has title=Reference | |||
| ?Mammal and model=Organism | |||
| ?Tissue and cell=Tissue;cell | |||
| format=broadtable | |||
| limit=5000 | |||
| offset=0 | |||
| sort=Was published in year | |||
| order=descending | |||
}} | |||
{{MitoPedia concepts | {{MitoPedia concepts | ||
|mitopedia concept=SUIT protocol, SUIT A, Find | |mitopedia concept=SUIT protocol, SUIT A, Find |
Revision as of 12:22, 20 February 2019
Description
Abbreviation: NS(PGM)
Reference: A
SUIT number: D042_1GM;2D;3P;4S;5U;6Rot;7Ama
O2k-Application: O2
- SUIT-category: NS(PGM)
- SUIT protocol pattern: diametral 1GM;2D;3P;4S;5U;6Rot;7Ama
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1GM | GML(n) | N | CI | 1GM
|
2D | GMP | N | CI | 1GM;2D
|
2c | GMcP | N | CI | 1GM;2D;2c
|
3P | PGMP | N | CI | 1GM;2D;2c;3P
|
4S | PGMSP | NS | CI&II | 1GM;2D;2c;3P;4S
|
5U | PGMSE | NS | CI&II | 1GM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1GM;2D;2c;3P;4S;5U;6Rot
|
7Ama | ROX | 1GM;2D;2c;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- Main fuel substrates
- » Glutamate, G
- » Glycerophosphate, Gp
- » Malate, M
- » Octanoylcarnitine, Oct
- » Pyruvate, P
- » Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + NS-OXPHOS capacity provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + The presence of PGM and S establishes fully operative TCA cycle activity.
- + This protocol allows to analyse the convergence of pathways at the Q-junction (N, NS, S).
- + Mitochondrial external membrane integrity can be measured with the addition of cytochrome c. Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- - It was observed that addition of P (5 mM) after GM inhibited respiration in horse skeletal muscle fibres (Votion et al 2012), which was not the case when P was titrated in steps of 1 mM.
- - When evaluating the additive effect of the N- and S-pathway, it has to be considered that NSP- and NSE-capacities can only be compared with NP- and SE-capacities. This is not a problem when NSP = NSE (Gnaiger 2009). Otherwise, it may be assumed that SP = SE (Votion et al 2012), such that NSP can be compared with NP + SP. SUIT-004 should be chosen for the additive effect in the ET-state.
- - Rox may be lower in substrate states earlier in the SUIT protocol. Therefore, this Rox measurement is frequently taken as a methodological control rather than as the final basis of Rox correction of mitochondrial respiration (mt).
- - Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.
- - CIV activity is not measured, to save experimental time.
Compare SUIT protocols
References
MitoPedia concepts: SUIT protocol, SUIT A, Find
MitoPedia methods:
Respirometry